|MDACC Study No:||2013-0843 (clinicaltrials.gov NCT No: NCT02096055)|
|Title:||Four-Arm Randomized Phase II Study of SGI-110: 5 days, versus 10 days, versus 5 days + idarubicin, versus 5 days + cladribine, in Previously Untreated Patients >/= 70 Years with Acute Myeloid Leukemia|
|Principal Investigator:||Hagop Kantarjian|
|Treatment Agent:||Cladribine; Idarubicin; SGI-110|
|Study Description:||The goal of this clinical research study is to compare different treatment |
schedules using the drug SGI-110 alone or in combination with other drugs.
Researchers want to learn more about how these different treatment schedules
may help to control AML. The safety of these treatments will also be studied.